US$1,443.50+1.3%11月13日 收盘
数据截至2026年9月30日，来自2026年10月29日提交的10-Q
Lilly discovers, makes, and sells prescription medicines for diseases including diabetes, obesity, cancer, and inflammatory conditions.
公司指引：2026 财年营收 US$91B 至 US$92B — 同比增长 40.4%
Just reported
From ELI Lilly & Co's results release of 2026年10月29日; its quarterly report has since been filed.
Actual
US$24.4B
+39% y/y
+6.2% q/q
Guided
—
No guide given
Actual
US$7.22
+16% y/y
-9.1% q/q
Guided
—
No guide given
Full year 2026
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$24.4B | US$17.6B | +38.61% |
| 利润 | US$6.5B | US$5.6B | +15.55% |
| 每股收益 | US$7.22 | US$6.21 | +16.26% |
| 自由现金流 | US$8.2B | US$6.7B | +21.80% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
每场电话会的简短摘要——本季度的表现、管理层的预期，以及他们是否兑现了上次所说的话——下方附完整文字记录。
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to en sure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news. F-LLY 7
公司自己的描述，取自公告末尾。
引述和公司简介来自 ELI Lilly & Co 于 2026年10月29日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
电话会摘要属于 Pro 内容
两分钟读完 ELI Lilly & Co 的每场业绩电话会：关键数字、管理层的预期、是否兑现了上季度的展望，以及分析师提出但未获回答的问题。
先在 , , , 或 上看一份——向所有人开放。
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。
Results released 2026年10月29日, before the market closed
Shares jumped as Lilly lifted 2026 revenue expectations on volume-led growth, while acquisition charges and price declines tempered the earnings outlook.
Into the report: +8.8% over a month, +11.7% over three months, -1.4% from the year's high.
What the full-year guide leaves · Earnings per Share
Like for like: No adjusted-definition change is identified; performance-margin guidance rose from 49.0%–50.5% in the August 2026 release to 52.0%–52.5% in the October 2026 release.
Written by AI on 2026年10月30日 from ELI Lilly & Co's results releases, earnings call and SEC filings; every quote it relied on was checked against them. It describes the report, it is not investment advice, and it is in English only.